| Autor: |
Markovic M; Clinic of Infectious and Tropical Diseases, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia., Ranin J; Clinic of Infectious and Tropical Diseases, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia., Bukumiric Z; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Institute of Medical Statistics and Informatics, 11000 Belgrade, Serbia., Jerotic D; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.; Centre for Excellence for Redox Medicine, Pasterova 2, 11000 Belgrade, Serbia., Savic-Radojevic A; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.; Centre for Excellence for Redox Medicine, Pasterova 2, 11000 Belgrade, Serbia., Pljesa-Ercegovac M; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.; Centre for Excellence for Redox Medicine, Pasterova 2, 11000 Belgrade, Serbia., Djukic T; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.; Centre for Excellence for Redox Medicine, Pasterova 2, 11000 Belgrade, Serbia., Ercegovac M; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Clinic of Neurology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia., Asanin M; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Clinic of Cardiology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia., Milosevic I; Clinic of Infectious and Tropical Diseases, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia., Stevanovic G; Clinic of Infectious and Tropical Diseases, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia., Simic T; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.; Centre for Excellence for Redox Medicine, Pasterova 2, 11000 Belgrade, Serbia.; Department of Medical Sciences, Serbian Academy of Sciences and Arts, 11000 Belgrade, Serbia., Coric V; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.; Centre for Excellence for Redox Medicine, Pasterova 2, 11000 Belgrade, Serbia., Matic M; Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.; Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.; Centre for Excellence for Redox Medicine, Pasterova 2, 11000 Belgrade, Serbia. |
| Abstrakt: |
In SARS-CoV-2 infection, excessive activation of the immune system intensively increases reactive oxygen species levels, causing harmful hyperinflammatory and oxidative state cumulative effects which may contribute to COVID-19 severity. Therefore, we assumed that antioxidant genetic profile, independently and complemented with laboratory markers, modulates COVID-19 severity. The study included 265 COVID-19 patients. Polymorphism of G STM1 , GSTT1 , Nrf2 rs6721961 , GSTM3 rs1332018 , GPX3 rs8177412, GSTP1 rs1695 , GSTO1 rs4925 , GSTO2 rs156697 , SOD2 rs4880 and GPX1 rs1050450 genes was determined with appropriate PCR-based methods. Inflammation (interleukin-6, CRP, fibrinogen, ferritin) and organ damage (urea, creatinine, transaminases and LDH) markers, complete blood count and coagulation status (d-dimer, fibrinogen) were measured. We found significant association for COVID-19 progression for patients with lymphocytes below 1.0 × 10 9 /L (OR = 2.97, p = 0.002). Increased IL-6 and CRP were also associated with disease progression (OR = 8.52, p = 0.001, and OR = 10.97, p < 0.001, respectively), as well as elevated plasma AST and LDH (OR = 2.25, p = 0.021, and OR = 4.76, p < 0.001, respectively). Of all the examined polymorphisms, we found significant association with the risk of developing severe forms of COVID-19 for GPX3 rs8177412 variant genotype (OR = 2.42, p = 0.032). This finding could be of particular importance in the future, complementing other diagnostic tools for prediction of COVID-19 disease course. |
